

Study type	Age	Study name and purpose	Location/ Sponsor	Contact/More info.	Basic inclusion criteria	Commitment	Status
Prevention	3-45	Hydroxychloroquine	UCSF	clinicalresearch@diabetes.ucsf.edu 844-T1D-UCSF (844-813-8273) or clinicaltrials.gov	Positive for 2 or more autoantibodies; not diagnosed with T1D.	Blood test and a box of pills for at home.	1/19/2022 enrollment open
Prevention	2.5-45	TrialNet: Pathway to Prevention Antibody Screening. Determines risk for developing T1D in family members, providing opportunities to join in further trials if at-risk	Worldwide	www.trialnet.org or clinicaltrials.gov	Have a relative with T1D (siblings, cousins, etc. may be at a higher risk of developing T1D)	Blood test at a center or at home (to mail in or take to LabCorp)	Available
Prevention	Any age	T1Detect: Antibody screening for anyone. To determine the risk for developing T1D	Worldwide	JDRF www.jdrf.org/t1d-resources/t1detect/	Screening for everyone	At home screening test kit for \$55.	Available
Drug	4-17	INHALE-1 (Afrezza): Fast acting inhaled insulin (already approved for adults)	Center of Excellence in Diabetes, Sacramento	Natalie Marlen 916-426-1902 or Dr. Prakasam (916) 426 1902, prakasg@sutterhealth.org clinicaltrials.gov	On multiple daily injections. A1C $\geq 7.0\%$ and $\leq 11\%$ Ave. dose of meal insulin ≥ 2 . On insulin at least six months.	26 weeks of Afrezza inhaled insulin or bolus injections for meals followed by 26 weeks of Afrezza for both groups.	Available 2/17/2022
Drug	14-45	Dompe: Oral Drug Ladarixin: thought to stop the inflammatory process and preserve beta cell function	Center of Excellence in Diabetes, Sacramento	Dr. Prakasam (916) 426 1902, prakasg@sutterhealth.org clinicaltrials.gov	T1D diagnosis in the last 120 days.	Ten study visits over a year, oral pill to take at home	12/1/2021 Available. Seeking 5 patients in Northern CA.
Drug	18-45	TOPPLE T1D: Testing to see if a plasmid injection can change the immune response, stopping the destruction of beta cells.	Stanford / UCSF	Stanford: Trudy Esrey, tesrey@stanford.edu, 650-498-4450, UCSF: clinicalresearch@diabetes.ucsf.edu 844-T1D-UCSF (844-813-8273)	Diagnosed within the past 4 years.	12 weekly injections.	08/23/2021 Available
Drug/Cure	18-65	Viacyte VC-02: The study will implant stem cell derived precursor beta cells in "pouches" under the skin. If effective, these cells will produce and allow insulin and other hormones into your bloodstream.	UC Davis	Prasanth N. Surampudi, MD, Work: 916-734-8328, Cell: 973-768-4821. psurampudi@UCDAVIS.EDU Additional info: www.youtube.com/watch?v=yA9Dhtph6MA	For patients that are hypo unaware or who have diabetes that is not well managed.	A surgeon will implant up to 12 units through up to 6 small incisions in your skin. 18 visits over 2 years. Immunosuppression drugs will be provided.	4/19/2021 Available. Seeking 10 participants.
Drug/Cure	18-65	Vertex: An islet cell infusion with immunosuppression. The goal of this infusion is to provide replacement cells for the ones that have been lost or don't work properly in people with diabetes.	Near Los Angeles (Duarte) - travel provided	https://t1dstudy.com/ , https://www.clinicaltrials.gov/ct2/show/NCT04786262	Episodes of severe low blood sugar (hypoglycemia) and impaired hypoglycemic awareness. A1C 7-9.5	1.5 week hospital stay, 90 minute cell infusion, quarterly visits for five years. Half of the visits can be with a home health nurse, half at the clinical trial center. Immunosuppression drugs will be provided.	5/26/2021 Available.

Study type	Age	Study name and purpose	Location/ Sponsor	Contact/More info.	Basic inclusion criteria	Commitment	Status
Drug (celiac and T1D)	14-80	T1D+CeD: Latiglutenase Treatment in Type 1 Diabetes Patients with Celiac Disease. The goal is to evaluate the efficacy of an oral therapeutic agent in drink form for protecting individuals with T1D and CD from intestinal and symptomatic distress they suffer due to minute ingestion of gluten protein.	Stanford	Franziska K Bishop: fbishop@stanford.edu, Nora Arrizon-Ruiz: narrizon@stanford.edu, or clinicaltrials.gov	T1D and Celiac and Celiac symptoms even with a gluten free diet	6 month study with an oral powder that mixes with water and periodic research visits.	10/26/2021 Available
Device	2-5	Tandem Control IQ	Stanford	Ryan Kingman: rkingman@stanford.edu Eliana Frank: elianaf@stanford.edu, Dr. Bruce Buckingham: bbendo@stanford.edu	Use of an insulin pump in the past 3 months. Use of Dexcom G6 for at least 11 out of the last 14 days.	Subjects will use the Tandem t: slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their blood sugar.	10/4/2021 just 12 spots available
Device	18-64	Prosciento: a new, infrared, non-invasive CGM	Santa Clara	https://myproscientostudy.com/t1-ed-009/ , hello@myproscientostudy.com, Claudia Camacho: Claudia.Camacho@prosciento.com, 619-600-6366	On an insulin pump. A1C>6 (they are also looking for non diabetic patients to trial)	8-9 weeks and includes 7 visits, paying out over \$2000	2/17/22 Available
Device	18-80	Medtronic Extended Wear Infusion Set Study. Evaluate a novel, long wear infusion set meant to last 6-7 days.	Stanford	diabetesresearch@stanford.edu, 408-655-8097	A1C under 8.5%. T1D at least 1 year. On 670G pump within 1 year prior to screening and willing to use auto mode and Guardian Sensor (3) during the study. Must be on Novolog or Humalog.	Participants will be given 12 experimental infusion sets to wear consecutively at home. 5 in-office visits, 2 phone calls.	
Device/Behavior	18-50	ONBOARD is for adults who are not currently using CGM (or using it but not consistently). The study provides 3 months of CGM supplies and testing out a behavioral intervention to see if it supports uptake and continued use of CGM (and the other benefits that can come along with that). The study is fully virtual.	Stanford (online)	onboardstudy@stanford.edu or Molly Tanenbaum, 650-725-3955 mollyt@stanford.edu	Not yet using CGM or not using CGM consistently.	Fully virtual study. Participants will be put in groups either "ONBOARD" or "CGM-only". Those in ONBOARD will schedule 4 60-minute sessions with study interventionist (every 2 weeks). A1c values, CGM usage data, and psychosocial data will be collected at baseline, 3-months (post-intervention),	4/19/2021 Available
Complications	18+	Various medications to treat painful diabetic neuropathy	Diablo Clinical Research	Caitlin Sheets: csheets@diabloclinical.com	Experiencing painful diabetic neuropathy. A1C 7-10	Studies are 6-8 months long, with 9-13 clinic visits	3/23/21 Available

Study type	Age	Study name and purpose	Location/ Sponsor	Contact/More info.	Basic inclusion criteria	Commitment	Status
Other	Any age	Gene sequencing to learn more about potential gene mutations related to T1D	UCSF (remote study)	Michael German: Michael.German@ucsf.edu	1) People with multiple immediate family members with T1D or 2) People with multiple auto-immune disorders (either 2+ or rarer disorders)	Spit in a vial and send it back to the lab. Can do from anywhere. Note: results are not provided but any mutations can be reported back to your Dr. to be followed-up on and retested at another lab.	12/1/2021 Available
Exercise	18-70	T1D Exercise Initiative. Study provides a watch and collects information during 2.5 hours of weekly exercise. Study data will be used to inform algorithms and future devices.	JAEB (at home study)	T1DEXI@jaeb.org, www.jaeb.org/t1dexi	T1D for more than 2 years Have or be willing to use Dexcom G6 CGM.	1 month at home study adding food/exercise info to an app, doing 6 short exercise videos / being active for 2 ½ hours a week. Compensation provided.	10/21/2020 Available
Diet	18+	Low fat plant based diet study. Comparing a plant based diet to a portion controlled diet.	Any location. Check ins at your local lab	Tatiana Znayenko-Miller, tznayenkomiller@pcrm.org, https://www.pcrm.org/clinical-research/recruitment	Not currently following a low fat, plant based diet	Weekly group sessions with physicians, dietitians, and cooking instructors. You will get nutrition education, practical tips, meal planning, and cooking demonstrations to help transition to a low-fat, plant-based diet. Participants will also schedule a one-on-one consultation with a dietitian and lab tests to check body composition and certain health measures.	1/19/2022 Available
Diet	19-30	Act1on Diet Types Study for T1D	Stanford	Nora Arrizon- Ruiz, narrizon@stanford.edu Brianna Leverenz: bleveren@stanford.edu; 650-724-1778	T1D for more than 1 year A1C <13% BMI 25-39	10.5 months, 5 in-person visits. \$700 compensation.	11/13/2020 Available
Behavior	7-18	4T's study: 12-month clinical trial to see if increased contact with our team, technology use, frequent data review, and optional exercise modules can improve clinical outcomes	Stanford	Brianna Leverenz: bleveren@stanford.edu; 650-724-1778	Diagnosed within the last 31 days, and are currently being seen at Stanford Children's Hospital & Clinics.	Complete 6 surveys, wear CGM	10/5/2020 Available
Behavior	13-19	The Insul-In This Together Study: The study is a family-based intervention designed to support families with type 1 teens and improve family dynamics and T1d management.	Stanford (online)	For more information: insulinthistogether@stanford.edu, 650-736-1517. Complete initial screening survey: here https://redcap.link/IITT	T1D teen and parent available.	Weekly 30 min. sessions held over 6 consecutive weeks. Surveys to complete online before, during, and after the sessions. A1C and CGM data to be provided.	1/19/2022 Available
Behavior	19+	EMBARK: Stress reduction and glycemic control	UCSF	1-855-850-3599, embark@ucsf.edu	Anyone with T1D over 19 years old	Online surveys and blood draws quarterly. 1-2 workshops, 4 web meetings.	10/7/2020 Available

Study type	Age	Study name and purpose	Location/ Sponsor	Contact/More info.	Basic inclusion criteria	Commitment	Status
Behavior	18+	Online survey to measure patient's perceptions of the risks and benefits of islet cell transplants.	UCSF (web based)	Leslie Wilson, Leslie.Wilson@ucsf.edu, diabetespreference.ucsf.edu/study-information	Have T1D, be over the age of 18. Have experienced severe hypoglycemic events (requiring assistance/medical intervention)	30 minute Online survey. \$20 compensation.	1/19/2022 Available
Behavior	5-12	Eddii: Eddi is an app to motivate kids around diabetes management. The eddii app connects to your child's CGM and has in-app games and rewards set by the parent. This research seeks to understand the effects of gamification and rewards on diabetes management.	Stanford (online)	<ul style="list-style-type: none"> • Farhaneh Ahmadi, PhD • study@eddiihealth.com • +1 (646) 409-6447 https://www.eddiihealth.com/leafstudy	<ul style="list-style-type: none"> • Your child must be 5 to 12 years old • Need access to an IOS device • Your child must wear a Dexcom CGM 	Participants will be asked to do the following: <ul style="list-style-type: none"> • Download the eddii app • Connect eddii to their child's CGM • Use the eddii app for 8 weeks • All study activities will take place remotely • Participants may be assigned to a control group 	1/28/2022 Available